RT Journal Article
T1 Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
A1 Lainez, Nuria
A1 García-Doñas, Jesús
A1 Esteban, Emilio
A1 Puente, Javier
A1 Sáez, M Isabel
A1 Gallardo, Enrique
A1 Pinto-Marín, Álvaro
A1 Vázquez-Estévez, Sergio
A1 León, Luis
A1 García-Carbonero, Icíar
A1 Suárez-Rodríguez, Cristina
A1 Molins, Carmen
A1 Climent-Durán, Miguel A
A1 Lázaro-Quintela, Martín
A1 González del Alba, Aranzazu
A1 Méndez-Vidal, María José
A1 Chirivella, Isabel
A1 Afonso, Francisco J
A1 López-Brea, Marta
A1 Sala-González, Nuria
A1 Domenech, Montserrat
A1 Basterretxea, Laura
A1 Santander-Lobera, Carmen
A1 Gil-Arnáiz, Irene
A1 Fernández, Ovidio
A1 Caballero-Díaz, Cristina
A1 Mellado, Begoña
A1 Marrupe, David
A1 García-Sánchez, José
A1 Sánchez-Escribano, Ricardo
A1 Fernández Parra, Eva
A1 Villa Guzmán, José C
A1 Martínez-Ortega, Esther
A1 González, María Belén
A1 Morán, Marina
A1 Suárez-Paniagua, Beatriz
A1 Lecumberri, María J
A1 Castellano, Daniel
K1 Adverse events
K1 Guidelines
K1 Renal Cell Carcinoma
K1 Targeted therapy
K1 Carcinoma de células renales
K1 Diarrea
K1 Hipertensión
K1 Neoplasias renales
K1 Cooperación del paciente
K1 Humanos
AB BACKGROUNDThe impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group (SOGUG) Guidelines for toxicity management of targeted therapies in metastatic renal cell carcinoma (mRCC) in daily clinical practice.METHODSData on 407 mRCC patients who initiated first-line targeted therapy during the year before and the year after publication and implementation of the SOGUG guideline program were available from 34 Spanish Hospitals. Adherence to SOGUG Guidelines was assessed in every cycle.RESULTSAdverse event (AE) management was consistent with the Guidelines as a whole for 28.7 % out of 966 post-implementation cycles compared with 23.1 % out of 892 pre-implementation cycles (p = 0.006). Analysis of adherence by AE in non-compliant cycles showed significant changes in appropriate management of hypertension (33 % pre-implementation vs. 44.5 % post-implementation cycles; p < 0.0001), diarrhea (74.0 % vs. 80.5 %; p = 0.011) and dyslipemia (25.0 % vs. 44.6 %; p < 0.001).CONCLUSIONSSlight but significant improvements in AE management were detected following the implementation of SOGUG recommendations. However, room for improvement in the management of AEs due to targeted agents still remains and could be the focus for further programs in this direction.
PB BioMed Central
YR 2016
FD 2016-02
LK http://hdl.handle.net/10668/2214
UL http://hdl.handle.net/10668/2214
LA en
NO Lainez N, García-Doñas J, Esteban E, Puente J, Sáez MI, Gallardo E, et al. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016; 16(1):135
NO Journal Article;
DS RISalud
RD Apr 8, 2025